Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 10;386(10):995-998.
doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26.

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita  1 , Noriko Kinoshita  2 , Seiya Yamayoshi  3 , Yuko Sakai-Tagawa  3 , Seiichiro Fujisaki  1 , Mutsumi Ito  3 , Kiyoko Iwatsuki-Horimoto  3 , Shiho Chiba  4 , Peter Halfmann  4 , Hiroyuki Nagai  3 , Makoto Saito  3 , Eisuke Adachi  3 , David Sullivan  5 , Andrew Pekosz  5 , Shinji Watanabe  1 , Kenji Maeda  2 , Masaki Imai  3 , Hiroshi Yotsuyanagi  3 , Hiroaki Mitsuya  2 , Norio Ohmagari  2 , Makoto Takeda  1 , Hideki Hasegawa  1 , Yoshihiro Kawaoka  6
Affiliations

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Similar articles

  • Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972 Free PMC article.
  • Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
    Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Takashita E, et al. N Engl J Med. 2022 Aug 4;387(5):468-470. doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857646 Free PMC article. No abstract available.
  • Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
    Ferré VM, Peiffer-Smadja N, Kramer L, Coppée R, Kante A, Debarge M, Choquet C, Saint Joannis T, Bouzid D, Messika J, Le Grand J, Thy M, Kernéis S, Descamps D, Visseaux B, Ghosn J. Ferré VM, et al. Microbiol Spectr. 2022 Oct 26;10(5):e0215222. doi: 10.1128/spectrum.02152-22. Epub 2022 Sep 20. Microbiol Spectr. 2022. PMID: 36125289 Free PMC article.
  • An overview of the development of pharmacotherapeutics targeting SARS-CoV-2.
    Lucaj T, Hay I, Samarbakhsh A, Bedi M, Iyer AK, Gavande NS. Lucaj T, et al. Drug Discov Today. 2024 Sep;29(9):104126. doi: 10.1016/j.drudis.2024.104126. Epub 2024 Aug 2. Drug Discov Today. 2024. PMID: 39097220 Review.
  • Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.
    Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Tiecco G, et al. Int J Mol Sci. 2022 Feb 11;23(4):1987. doi: 10.3390/ijms23041987. Int J Mol Sci. 2022. PMID: 35216104 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. December 7, 2021. (https://www.who.int/publications/m/item/weekly-epidemiological-update-on...).
    1. Qin S, Cui M, Sun S, et al. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529). Zoonoses, December 3, 2021. (https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2021-0024).
    1. Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 2021;184:3086-3108. - PMC - PubMed
    1. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021;596:276-280. - PubMed
    1. Bansal K, Kumar S. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant. December 7, 2021. (https://www.biorxiv.org/content/10.1101/2021.12.06.471389v1). preprint. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts